4.1. Domestic monitoring of vital signs in hypoglycemia
Diabetes is a metabolic disorder characterized by high blood glucose that affects, today, around half a billion persons worldwide, with an estimated year cost of 10% of the global health expenditure. Type 1 diabetes (T1D) is due to insulin deficiency and is treated pharmacologically by insulin administration, which in any case cannot replicate the physiological secretion and thus leads to glucose oscillations. Hypoglycemia (HG) is a major threat in T1D patients and commonly occurs in clinical practice as approximately 90% of all patients who receive insulin [
50]. In average, individuals with T1D experience about two episodes of symptomatic hypoglycemia per week. The prevalence of severe hypoglycemia, which necessitates assistance for recovery, is approximately 30-40% annually, with an incidence of 1.0-1.7 episodes per patient per year. The likelihood of experiencing this risk increases considerably with prolonged disease duration [
51]. Symptoms of hypoglycemia can be mainly divided in two categories: neurogenic (autonomic) and neuroglycopenic. Neuroglycopenic symptoms are caused by brain glucose deprivation and include cognitive impairment (altered perception, poor concentration, slow speech, slow decision-making), behavioral changes (irritation, frustration), psychomotor abnormalities (weakness, incoordination), seizure/coma and permanent neurological damage for prolonged severe hypoglycemia [
52]. Neurogenic symptoms on the other hand are caused by the sympathoadrenal response and include adrenergic symptoms (palpitations, tremulousness, anxiety, arousal, skin pallor/flushing or blotchy rashes, tingling around the mouth/lips) and cholinergic symptoms (sweating, hunger, paresthesia) [
52].
Nocturnal HG is particularly dangerous because symptoms are typically blurred by sleep, sometimes resulting in coma and even death. It is known that during the transition to HG, in order to bring blood sugar level back up to normal, the body elicits a hormonal response which in turn leads to a number of symptoms. These include heart rate variability, progressive degradation of cognitive functionality and cerebral activity.
To get deeper insight into evolution of vital signs during transition to HG condition, we propose a wearable system based on QVAR sensors recording electrocardiogram and electroencephalogram during the night, for use in domestic environment. The strategy would be to correlate those biopotentials to the level of glucose in blood measured instantaneously by a glucose sensor. Some authors identified a meaningful set of parameters to be extracted from ECG and EEG traces in time and in frequency domains, that have been observed to alter before the onset of a HG episode. From ECG, they focused on the QT
c interval length, the RR tract, the HR and the HRV with its standard deviation normal to normal (SDNN) and its root mean square (RMSSD) and, finally, the low/high-frequency ratio (LF: HF) of the HRV power spectrum [
53,
54,
55,
56,
57,
58,
59,
60,
61]. Regarding the EEG, only few authors reported results starting from the power spectrum of α-waves and calculating the frequency centroid CF (and the spectral rotational radius derived from spectral moments G0 and higher) [
62,
63,
64].
The hardware of our system consists of two boards, each integrating a Qvar sensor, a microcontroller, a battery, a microSD memory. The two boards are fixed on the chest: one sensor acquires ECG with two electrodes in RA-LA positions, the other sensor acquires the α-wave EEG with two electrodes on the occipital sites O1 and O2. Data are all stored in the microSD. Preliminary verification of the correct operation of the QVAR system was performed on control subjects, by comparison with a gold standard (Cyton BCI, in this case).
Table 3 summarizes values of the parameters calculated from ECG and EEG averaged in 24-hour acquisition on six control subjects: as one can see, the agreement is excellent, with a discrepancy lower than 1.5%.
In
Figure 9 the RR trait duration extracted from ECG with our system (top) and the gold standard (bottom) are compared in time and frequency domain. In the same figure, the α-wave ECG recorded with our system (top) and the gold standard (bottom) are compared in time and frequency domain.
Table 3.
Values of main ECG/EEG parameters averaged in 24 hour acquisition on six control subjects.
Table 3.
Values of main ECG/EEG parameters averaged in 24 hour acquisition on six control subjects.
After those preliminary tests, a T1D patient was studied overnight in domestic environment. He was male, 63 years old, diagnosed at 22, treated with insulin pump and a glucose target value of 120 mg/dl (this relatively high value should not surprise, since each diabetic patient has a specific glucose reference value and a specific hypoglycemia threshold). The patient always puts on a glucose sensor (GS) on an arm, recording the glucose value every minute, whose hypoglycemic alarm is set at 80 mg/dl.
The patient gave informed consent to be tested with our device. So, throughout testing nights, he was wearing the QVAR system in addition to the gold standard and the GS. At a certain time (which hereafter will be referred to as t=0), the glucose reached the critical threshold and the GS alarmed the patient, who woke up and immediately assumed sugar. In
Figure 10 and in
Figure 11 we show values of the ECG parameters (LF:HF, SDNN) and EEG parameter (CF) reported by the QVAR system and the gold standard before the alarm (orange curves). In the same figures, the glucose data recorded by the GM are also drawn with blue solid line. The intervals where ECG and EEG parameters underwent meaningful variation are highlighted with pink shadows and the trends are indicated with dashed lines.
As one can see, the ECG underwent a slow and progressive variation long before the glucose approached the critical value (approximately 90 minutes before, when the glucose decreased below the value of 100 mg/dl), while the α-wave EEG exhibited a sudden variation only 15 minutes before the alarm.
At this stage, any conclusion from the clinical viewpoint would be meaningless, since would require much further study and many more patients (beyond the target of this paper), but, on the contrary, the technological conclusion is that our wearable system using QVAR sensors can efficiently monitor simultaneously ECG and EEG channels, allowing to study vital signs before and during nocturnal HG crisis, in domestic environment.
Figure 10.
Values of the ECG parameters (LF:HF, SDNN) displayed before the alarm (t=0). In the same figures, the glucose data recorded by the GM is also drawn with blue solid line. The dashed line indicates the trends of variation of the studied parameters.
Figure 10.
Values of the ECG parameters (LF:HF, SDNN) displayed before the alarm (t=0). In the same figures, the glucose data recorded by the GM is also drawn with blue solid line. The dashed line indicates the trends of variation of the studied parameters.
Figure 11.
Values of the EEG parameter (CF) displayed before the alarm (t=0). In the same figure, the glucose data recorded by the GM is also drawn with blue solid line. The dashed line indicates the trend of variation of the studied parameter.
Figure 11.
Values of the EEG parameter (CF) displayed before the alarm (t=0). In the same figure, the glucose data recorded by the GM is also drawn with blue solid line. The dashed line indicates the trend of variation of the studied parameter.
4.2. Domestic monitoring of non-EEG biopotentials for REM/NREM sleep screening
Sleep can be disrupted by various disorders that are classified based on the stage of sleep during which they manifest (i.e., rapid eye movement - REM and non-rapid eye movement – NREM sleep phase). These disorders exhibit distinct pathophysiological mechanisms and prognosis, and require specific therapeutic interventions [
65]. Accordingly, accurate diagnosis and treatment of different sleep disorders crucially depends on the ability to properly differentiate between sleep phases. One notable example is REM Sleep Behavior Disorder (RBD), a parasomnia occurring during the REM sleep stage, particularly significant for neurologists, psychiatrists, and geriatricians. Indeed, RBD is acknowledged as a precursor to neurodegenerative diseases such as Parkinson’s disease, dementia with Lewy body and multiple system atrophy [
66,
67]. Manifesting as dream enactment behavior [
66], patients with RBD engage in activities like screaming, speaking, falling, and mimicking dream motions, often resulting in injuries and violence.. The diagnosis of RBD is usually challenging, necessitating a history of complex sleep behaviors confirmed during REM sleep. REM sleep should be therefore demonstrated, with the contemporary absence of atonia by evidencing dream enactment behavior [
68]. The gold standard for the diagnosis of sleep disorders is polysomnography (PSG), according to the American Association of Sleep Medicine (AASM) scoring guidelines. However, PSG is a cumbersome test available in (a very limited number of) medical centers, requiring specialized supervision and leading to prolonged waiting times. Indeed, access difficulties to the PSG contribute to undiagnosed and untreated sleep disorders, with significant consequences. Moreover, it is demonstrated that the environment influences the sleep quality [
69], so that the PSG itself may result distorted by the altered emotional state of the hospitalized subject. Accordingly, the challenge with diagnosing RBD extends beyond the need for hospitalization to conduct PSG. Indeed, even after the test is performed, it may result not effective since symptoms do not always appear, necessitating extended hospital stays for an accurate diagnosis. As a consequence, RBD still remains largely undiagnosed [
70], like many other sleep-related disorders. Since RBD may precede specific neurodegenerative diseases by several years, recognizing it becomes crucial for identifying at-risk patients during a preclinical phase. The early identification of individuals at risk for neurodegenerative disorders would allow the development and administration of novel neuroprotective drugs, potentially delaying or preventing the onset of specific diseases [
71].
Due to all these factors, the field of telemedicine is currently focusing on more widespread screening and home monitoring approaches for sleep disorders [
69,
72,
73]. The aim is to support clinicians in their diagnostic procedures. Domestic screening facilities would play a crucial role in identifying individuals at-risk who really and urgently need hospitalization for the diagnosis, thus optimizing the utilization of limited PSG resources and the expertise of trained personnel. This approach would reduce waiting times from recognition to diagnosis and treatment of sleep disorders, ultimately increasing adherence to treatment, despite a growing number of sleep consults [
74,
75]. In the last few years, portable solutions and systems for domestic screening, detecting and/or remote monitoring sleep have been proposed. These can be categorized into two main categories: those using EEG and those that do not.
As mentioned earlier, PSG provides the most accurate and comprehensive insights into sleep patterns. It identifies the REM stage by detecting epochs characterized by low-amplitude, mixed-frequency EEG, low chin/masseter EMG tone and rapid eye movements [
76]. On the opposite side, we find examples of extremely less accurate wearable devices, as the commercial sleep trackers (CST), which do not use EEG and focus on fitness rather than on healthcare. These devices rely on measuring the heart rate (HR), HR variability (HRV) and movements using photoplethysmography (PPG) and inertial sensors. While they can distinguish between wake and sleep phases [
77,
78,
79,
80,
81,
82,
83,
84,
85], they are totally unaffordable for comprehensive analysis of sleep [
86,
87,
88]. With this information, it is clear that HR, HRV and movements are not fully representative of the REM phase. Using artificial intelligence (AI) can probably increase accuracy of REM staging when the set of data collected is not exhaustive, as demonstrated by some authors [
89,
90,
91,
92]. However, it is essential to consider that these studies are still at a preliminary stage.
In summary, PSG is the gold standard and EEG is the biopotential validated by doctors for sleep analysis. On the opposite, CST mounting PPG and accelerometers are most popular option, able to distinguish sleep/wake, but unable to identify the REM stage and not clinically accepted. To improve accuracy of REM staging by wearable technology, it would be desired to consider other markers in addition to HR/HRV and movement, without penalizing cost, comfortability and wearability in comparison to CST.
In this scenario, we propose a wearable device using three QVAR sensors designed for recording three biopotentials: the EOG, the surface EMG (sEMG), and the ECG. The EOG, used to assess rapid eye movements, can be accurately captured from the Fp1 and Fp2 derivations of the 10-20 international system. To assess muscle atonia, the sEMG can be taken from the masseter or mentalis muscles. The ECG, essential to derive HR and HRV, can be recorded using any derivation. The proposed device follows the strategy of comfort adopted by CST, while adding value through the inclusion of EOG and sEMG, at no additional cost. Leveraging the MEMS technology, the QVAR sensors are embedded in accelerometers and are on the market at the same price. Furthermore, the minimal power consumption of a QVAR sensor during recording (27 µW) ensures that the energy expenditure is negligible, thus presenting a cost-effective solution compared to inertial acquisitions.
Our system is contained into an elastic headband, as illustrated in
Figure 12. This headband includes a Mini Nucleo L031K6 board by STMicroelectronics, which embeds a Cortex M0 microcontroller, and three QVAR sensors for acquiring the EMG, the ECG, the EOG.
The electrodes on the masseter (M1, M2) for the EMG and the electrodes on the chest (RA, LA) for the ECG are shown in the photograph by the side. Electrodes on the frontal regions (Fp1, Fp2) for the EOG are inside the headband, in contact with the forehead skin. The ECG provides a comprehensive overview of the heart rate which could be also detected through a PPG sensor in order to reduce wiring despite increased power consumption. The QVARs transmit data to the Nucleo through I2C standard. Each QVAR acquires the corresponding biopotential at a sampling frequency of 240 Hz, utilizing a two-electrode configuration. The reference voltage for QVARs is provided by the on-board circuitry, avoiding the third reference electrode.
Tests were performed on a control subject over consecutive nights. A result of main interest is reported in
Figure 13. This figure represents a specific 45-minute timeframe during a night, which starts approximately 3 hours after the subject fell asleep. The graphical representation reports the traces of the three biopotentials as a function of time, covering the interval from 3:10 to 3:55 a.m. (in these figures, the time scale has an internal origin). When considering the HR, derived from the trace recorded by QVAR 1, initially HR remains below 55 bpm in the first minutes, then, at 3:28, the HR exhibits a wide variability with bursts reaching up to 80 bpm. This interval of pronounced HRV stops at 3:45, after which HR reverts to values below 55 bpm. The 17-minute interval between 3:28 and 3:45 is highlighted with a grey shadow. Concerning the eye activity, detected by the QVAR 2, the EOG signal remains close to zero for the initial 8 minutes, indicating an absence of eye movements. Then, around 3:28, there is a substantial increase in eye activity, stopping at 3:45. Lastly, regarding the masseter tone detected by the QVAR 3, in the shadowed interval, the masseter manifests a total atonia, while in other intervals a residual constant contraction is present. The
simultaneous occurrence of all the three patterns was an extraordinary event, presenting only two times throughout the night of testing, with durations of 17 and 15 minutes. On the contrary, in other intervals of variable durations, frequent changes in the individual signals under consideration occurred. In particular, QVAR 1 often recorded pronounced variability of HR, underscoring the limitations of CST in accurately analyzing sleep patterns.